Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05037305 · ClinicalTrials.gov registry record · NA
VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey
A NA study of Pharmacogenomic Testing, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 2
- Study locations
NCT05037305: Active NA study of Pharmacogenomic Testing, sponsored by Vanderbilt University Medical Center.
NCT05037305 is a NA study of Pharmacogenomic Testing that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 500 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05037305, a NA study of Pharmacogenomic Testing, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The field of pharmacogenetics has progressed from the discovery of genetic variants that cause variable function of drug metabolism enzymes to a cornerstone of clinical precision medicine. However, there are limited data supporting drug-gene associations for children and for women during and after pregnancy. The unique physiology of childhood and pregnancy demand validation of pharmacogenetic signals prior to clinical implementation. These knowledge gaps are compounded for individuals from minority populations, who have been underrepresented and thus underserved by genomic research and specifically pharmacogenetic studies. The primary objective of this project is to advance research and support clinical implementation in pharmacogenetics for children and pregnant women. This work will illuminate knowledge of, attitudes about, and priorities for pharmacogenetics, and will assess the impact of a brief educational video on knowledge and attitudes around pharmacogenetic testing. The investigators will assess the knowledge and attitudes regarding pharmacogenetic testing among diverse cohorts of children with chronic conditions and pregnant women, before and after receiving pharmacogenetic test results. Participants will be randomized to view an educational video about pharmacogenetic testing either at the time of receiving their pharmacogenetic test results, or at a later time. The investigators will perform surveys before and after pharmacogenomic testing and return of results, and before and after watching the educational video.
Primary Outcome
* Opinion of Knowledge of Pharmacogenetics (PGx) and Related Terminology is being collected in 3 ways. Ten words or phrases will be assessed using a 5-variable ordinal scale ('Not at all familiar' to 'Extremely familiar'). One question will use a 4-variable ordinal scale (Very well, somewhat well, a little, not at all). Another question will use a 5-option Likert scale (A lot, somewhat, a little, not at all, don't know). * Opinion of the Usefulness of PGx Testing is being collected using 12 stat
Conditions Studied
Interventions
- OTHER Educational video
Study Locations (2)
Tennessee
- Monroe Carell Jr. Children's Hospital at Vanderbilt - Nashville
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
What the registry record for NCT05037305 still lists
NCT05037305 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Pharmacogenomic Testing appearing as the primary indexed condition, and to 1 intervention - of which Educational video is the first listed.
NCT05037305 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05037305 about?
NCT05037305 is a clinical study titled "VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey". The field of pharmacogenetics has progressed from the discovery of genetic variants that cause variable function of drug metabolism enzymes to a cornerstone of clinical precision medicine. However, there are limited data supporting drug-gene associations for children and for women during and after p...
What is the current status of trial NCT05037305?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2022-06-30. Estimated completion is 2026-04-30.
What conditions does trial NCT05037305 study?
This clinical trial studies the following conditions: Pharmacogenomic Testing.
What interventions are being tested in trial NCT05037305?
The interventions under investigation include: Educational video (OTHER).
Who is sponsoring clinical trial NCT05037305?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05037305 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacogenomic Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05037305's enrollment target sits among peer trials
500 193rd of 2000 higher than 1,788 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI